JiangSu WuZhong Pharmaceutical Development Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
JiangSu WuZhong Pharmaceutical Development Co., Ltd. carries a market capitalization of 206.16M, placing it among publicly traded companies globally. Its enterprise value stands at 3.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 206.16M |
| Enterprise Value | 3.33B |
Share Statistics
JiangSu WuZhong Pharmaceutical Development Co., Ltd. currently has 712.15M shares outstanding.
| Shares Outstanding | 712.15M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
JiangSu WuZhong Pharmaceutical Development Co., Ltd. trades at a trailing price-to-earnings ratio of 1,111.04. The price-to-sales ratio is 1.74, and the price-to-book ratio stands at 7.17.
| PE Ratio | 1,111.04 |
| PS Ratio | 1.74 |
| PB Ratio | 7.17 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | 56.29 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, JiangSu WuZhong Pharmaceutical Development Co., Ltd. trades at an EV/EBITDA multiple of 21.16 and an EV/FCF ratio of 94.21. The EV/Sales ratio of 3.23 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 21.16 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.23 |
| EV / EBITDA | 21.16 |
| EV / EBIT | 21.16 |
| EV / FCF | 94.21 |
Financial Position
JiangSu WuZhong Pharmaceutical Development Co., Ltd. maintains a current ratio of 1.51, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 84.86, indicating elevated leverage, while an interest coverage ratio of 2.48 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.51 |
| Quick Ratio | 0.06 |
| Debt / Equity | 84.86 |
| Debt / EBITDA | 9.97 |
| Interest Coverage | 2.48 |
Financial Efficiency
| Return on Equity (ROE) | 0.65 |
| Return on Assets (ROA) | 0.04 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 7.25 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.23 |
Taxes
Over the trailing twelve months, JiangSu WuZhong Pharmaceutical Development Co., Ltd. has paid -21.15M in income taxes, reflecting an effective tax rate of 20.46.
| Income Tax | -21.15M |
| Effective Tax Rate | 20.46 |
Stock Price Statistics
JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s stock has declined approximately -96.81668% over the past 52 weeks. The 50-day moving average sits at 0.87, while the 200-day moving average is 1.98.
| Beta (5Y) | N/A |
| 52-Week Price Change | -96.81668% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 1.98 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, JiangSu WuZhong Pharmaceutical Development Co., Ltd. generated 1.03B in revenue and converted that into 1.61M in net income, yielding earnings per share of 0.03. EBITDA reached 157.18M, while operating income came in at 157.18M.
| Revenue | 1.03B |
| Gross Profit | 832.16M |
| Operating Income | 157.18M |
| Pretax Income | -916,544.98 |
| Net Income | 1.61M |
| EBITDA | 157.18M |
| EBIT | 157.18M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
JiangSu WuZhong Pharmaceutical Development Co., Ltd. holds 110.48M in cash and equivalents against 1.57B in total debt, resulting in a net debt position of 1.33B. Total book value stands at 249.69M, with working capital of 893.09M providing operational flexibility.
| Cash & Cash Equivalents | 110.48M |
| Total Debt | 1.57B |
| Net Debt | 1.33B |
| Equity (Book Value) | 249.69M |
| Book Value Per Share | 0.35 |
| Working Capital | 893.09M |
Cash Flow
After subtracting -31.80M in capital expenditures, free cash flow totaled -31.80M - equivalent to -0.04 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -31.80M |
| Free Cash Flow | -31.80M |
| FCF Per Share | -0.04 |
Margins
JiangSu WuZhong Pharmaceutical Development Co., Ltd. operates with a gross margin of 80.92, reflecting its pricing power and cost economics. The operating margin of 15.28 and net profit margin of 0.16 provide insight into operational efficiency.
| Gross Margin | 80.92 |
| Operating Margin | 15.28 |
| Pretax Margin | -0.09 |
| Profit Margin | 0.16 |
| EBITDA Margin | 15.28 |
Dividends & Yields
The company's payout ratio of 150.70 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.08 |
| Dividend Yield | N/A |
| Payout Ratio | 150.70 |
| Shareholder Yield | 12.76 |
| FCF Yield | 1.78 |
Stock Splits
JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s most recent stock split took place on September 7, 2006 with a 2:3 split ratio.
| Last Split Date | 9/7/2006 |
| Split Ratio | 2:3 |
Scores
JiangSu WuZhong Pharmaceutical Development Co., Ltd. posts an Altman Z-Score of 1.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.10 |